EX-FILING FEES 5 tm2218996d2_ex-filingfees.htm EX-FILING FEES

 

Exhibit 107

 

Calculation of Registration Fee

 

Form S-3

(Form Type)

 

Vaccitech plc

(Exact name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

    Security
Type
  Security
Class
Title
  Fee
Calculation
or Carry
Forward
Rule
  Amount
Registered
    Proposed
Maximum
Offering
Price Per
Share (2)
    Maximum
Aggregate
Offering Price
    Fee Rate     Amount of
Registration
Fee
    Carry
Forward
Form
Type
  Carry
Forward
File
Number
  Carry
Forward
Initial
effective
date
  Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward
Newly Registered Securities
Fees to Be Paid   Equity   Ordinary shares, nominal value £0.000025 per share(1)   Rule 457(c)     2,163,694     $ 4.305     $ 9,314,702.67       0.0000927     $ 863.47                  
Fees Previously Paid                                                    
Carry Forward Securities
Carry Forward Securities                                                    
    Total Offering Amounts             $ 9,314,702.67             $ 863.47                  
    Total Fees Previously Paid                                                
    Total Fee Offsets                                                
    Net Fee Due                             $ 863.47                  

 

(1)

The ordinary shares registered hereby are evidenced by American Depositary Shares (“ADSs”). ADSs, each representing one ordinary share, have been registered on a separate registration statement on Form F-6 filed with the Securities and Exchange Commission and which became effective on April 29, 2021 (File No. 333-255237).

 

(2) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) of the Securities Act. The price per share and maximum aggregate offering price are based on the average of the high and low prices of the registrant’s ADSs on June 14, 2022, as reported on The Nasdaq Global Market.